Maverix logo
Cirrus Bio develops and brings to market multiomic solutions for the diagnosis and management of diseases where early detection plays a critical role in clinical outcomes. The founders of Cirrus Bio,
As part of the acquisition, Maverix also announced the formation of a dedicated diagnostic division called Maverix Dx that will develop, invest in, acquire, and bring to market a suite of diagnostic tools for lung cancer.
'Lung cancer remains the largest cancer killer, by far. The only way to improve survival rates for this extremely aggressive disease is to catch it early and act decisively. This acquisition gives Maverix unparalleled technology, talent, and expertise in early cancer detection, and will serve as the foundation for a broader diagnostic portfolio with the potential to transform lung cancer care,' said
Cirrus represents the second major new product platform for Maverix. The first-Serpex Medical, announced at closing-has developed and obtained 510k clearance for steerable technologies that can precisely target lung tissue for biopsy or therapy delivery. Serpex will continue to serve as the foundation for the medical device division of Maverix, called Maverix Med Device, led by Serpex founder and CEO
'As we evaluate the lung cancer market, we see tremendous unmet clinical need and a rich opportunity set for both internal development and acquisitions. We are far from the only ones working on this tough clinical problem, and we look forward to partnering with other innovators to discover and validate new techniques for improving lung cancer care,' said
With the support of its financial sponsors and advisors, KKR and Hologic, Maverix Medical continues to invest in both development- and commercial-stage lung cancer companies and welcomes opportunities to collaborate with innovators, entrepreneurs, clinicians, and industry leaders.
Contact:
Diagnostic Inquiries
CEO
Maverix DX
dmallery@maverixmedical.com
Medical Device Inquiries
Sasha Schrode
CEO, Maverix Med Device
sschrode@maverixmedical.com
(C) 2024 Electronic News Publishing, source